{"id":"W2136385642","doi":"10.1517/14712598.2012.657622","title":"Obinutuzumab for the treatment of lymphoproliferative disorders","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Obinutuzumab; Rituximab; Medicine; Antibody-dependent cell-mediated cytotoxicity; CD20; Clinical trial; Lymphoma; Oncology; Monoclonal antibody; Immunology; Monoclonal antibody therapy; Internal medicine; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009714872,0.000543408,0.001691386,0.00006188104,0.0001249158,0.00001103253,0.0001437114,0.0003755763,0.000195834],"category_scores_gemma":[0.00001824162,0.0001943714,0.001359314,0.0001189716,0.0001529015,0.00001465221,0.00001196599,0.00005396312,0.00003208983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000700042,"about_ca_system_score_gemma":0.0001811722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002770355,"about_ca_topic_score_gemma":4.954013e-7,"domain_scores_codex":[0.998485,0.0001544764,0.0004708662,0.0004194711,0.0001535427,0.0003166446],"domain_scores_gemma":[0.9978395,0.001266177,0.0002568605,0.0004863021,0.00004022409,0.0001110027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004403341,0.002352669,0.00003586712,0.00005759236,0.0009977716,5.784509e-7,0.0002054998,1.095863e-7,8.319969e-7,0.0008714508,0.0004489084,0.9945884],"study_design_scores_gemma":[0.003206939,0.01003181,0.0001014087,0.0007286714,0.00002574175,0.00001054922,0.00003260496,0.000001689667,0.00005509185,0.00003730388,0.9855673,0.0002008287],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002732983,0.9940792,0.000016624,0.0003924023,0.0007326926,0.004383258,0.00009602461,0.00003850581,0.0002339601],"genre_scores_gemma":[0.0002947686,0.9922414,0.000124762,0.0003265515,0.0009098382,0.005591443,0.0004286903,0.00003493287,0.00004763435],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9943876,"threshold_uncertainty_score":0.7926234,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2809002386474803,"score_gpt":0.4416714715049894,"score_spread":0.1607712328575091,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}